Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Pacific Biosciences Of California Inc. (PACB): Bridger Management Ups Its Stake

Page 1 of 6

According to a newly-amended 13G filing with the US Securities and Exchange Commission,  Roberto Mignone‘s Bridger Management owns 4.46 million shares of Pacific Biosciences Of California Inc. (NASDAQ:PACB), which account for 5.1% of the company’s 86,99 million shares the company reported outstanding as of April 1. The position compares to some 2.16 million shares Bridger disclosed in its 13F filing for the end of the fourth quarter.

Pacific Biosciences of California is a biotechnology company that invents and creates sequencing systems in order to help scientists resolve genetically complex issues, and some of its technology enables single molecule, real time discovery of a variety of biological processes. Over the past 12 months, the company’s shares have increased by 80.3%. Last week, Pacific Biosciences of California reported its first-quarter results and even though the company posted a loss of $0.23 per share, it was better than the expected loss of $0.25 per share, while the revenue of $19.10 million topped the estimates of $18.02 million.

At the end of December, 18 funds tracked by Insider Monkey 18 reported long positions in Pacific Biosciences Of California Inc. (NASDAQ:PACB) up from 11 funds a quarter earlier. Lee Ainslie’s Maverick Capital held the biggest position, valued at $99.3 million, and Mitchell Blutt’s Consonance Capital Management, reported the second-largest stake valued at about $72.2 million in stock. Other money managers that are bullish on this stock were Jim Simons’s Renaissance Technologies and James E. Flynn’s Deerfield Management, Ken Greenberg and David Kim’s Ghost Tree Capital, Phill Gross and Robert Atchinson’s Adage Capital Management, and Dmitry Balyasny’s Balyasny Asset Management.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Bridger Management 0 4,462,170 0 4,462,170 4,462,170 5.1%
Roberto Mignone 0 4,462,170 0 4,462,170 4,462,170 5.1%

Roberto Mignone
Roberto Mignone
Bridger Management

Page 1 of 6 – SEC Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934

Pacific Biosciences of California, Inc.


(Name of Issuer)

Common Stock, par value $0.001 per share


(Title of Class of Securities)

69404D108


(CUSIP Number)

April 15, 2016


(Date of Event which requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Follow Pacific Biosciences Of California Inc. (NASDAQ:PACB)
Trade (NASDAQ:PACB) Now!
Page 1 of 6
Loading Comments...